Group One Trading’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.29M Buy
108,100
+108,000
+108,000% +$4.98M 0.01% 1132
2025
Q4
$4.48K Sell
100
-25,200
-100% -$1.06M ﹤0.01% 7227
2025
Q3
$1.02M Buy
25,300
+22,700
+873% +$800K ﹤0.01% 3017
2025
Q2
$81.4K Buy
+2,600
New +$84.8K ﹤0.01% 5153
2024
Q3
Sell
-5,000
Closed -$195K 7461
2024
Q2
$195K Sell
5,000
-10,800
-68% -$432K ﹤0.01% 3406
2024
Q1
$680K Sell
15,800
-101,500
-87% -$4.67M ﹤0.01% 2444
2023
Q4
$5.4M Buy
117,300
+66,000
+129% +$2.33M 0.01% 1074
2023
Q3
$1.75M Buy
51,300
+46,000
+868% +$1.72M 0.01% 1754
2023
Q2
$204K Buy
+5,300
New +$211K ﹤0.01% 3907
2023
Q1
Sell
-26,800
Closed -$1.06M 8054
2022
Q4
$1.06M Sell
26,800
-40,200
-60% -$1.46M ﹤0.01% 2365
2022
Q3
$2.42M Buy
67,000
+8,400
+14% +$302K ﹤0.01% 1748
2022
Q2
$1.78M Buy
58,600
+9,600
+20% +$290K ﹤0.01% 2163
2022
Q1
$1.5M Buy
49,000
+39,700
+427% +$1.19M ﹤0.01% 2690
2021
Q4
$291K Sell
9,300
-17,500
-65% -$523K ﹤0.01% 4692
2021
Q3
$410K Buy
+26,800
New +$466K ﹤0.01% 4415

Other funds holding XENE

Group One Trading's XENE Position: Q4 2025 in Review

Group One Trading sold out of Xenon Pharmaceuticals (XENE) in Q4 2025, closing a stake of 3,556 shares — an estimated $149K sold.

Group One Trading first reported a position in XENE in Q2 2021 and held it in 10 quarters. The position peaked at $418K in Q3 2022. 246 funds tracked by Wall St. Rank hold XENE as of Q4 2025.

  • Group One Trading reported no remaining Xenon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 3,556 Xenon Pharmaceuticals shares in Q4 2025, an estimated $149K.
  • Group One Trading first reported a position in Xenon Pharmaceuticals in Q2 2021 and held it in 10 quarters.
  • Group One Trading's Xenon Pharmaceuticals position peaked at $418K in Q3 2022.
  • 246 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.